上海览屹医药科技

Lanyi Pharma is a Shanghai-based biotechnology company specializing in the discovery and development of small molecule drugs targeting protein-protein interactions (PPI). Founded in 2021, the company utilizes a proprietary platform to address "undruggable" targets through allosteric regulation and structural biology-driven design. Their primary therapeutic focus is on oncology and immunology, aiming to provide novel treatments for patients with high unmet medical needs. The company has secured significant venture capital funding from prominent investors like Matrix Partners China and Qiming Venture Partners. Headquartered in the Zhangjiang Hi-Tech Park, Lanyi Pharma integrates computational chemistry and high-throughput screening to accelerate its drug discovery process.